Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Author： Mottamal Madhusoodanan   Zheng Shilong   Huang Tien L.   Wang Guangdi  

Publisher： MDPI

E-ISSN： 1420-3049|20|3|3898-3941

ISSN： 1420-3049

Source： Molecules, Vol.20, Iss.3, 2015-03, pp. : 3898-3941

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone Deacetylase Inhibitors as Anticancer Drugs

By Eckschlager Tomas   Plch Johana   Stiborova Marie   Hrabeta Jan  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1414-1414

MDPI

Access to resources Recommend Favorite

Clinical Toxicities of Histone Deacetylase Inhibitors

By Subramanian Srividya   Bates Susan E.   Wright John J.   Espinoza-Delgado Igor   Piekarz Richard L.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-08 ,pp. : 2751-2767

MDPI

Access to resources Recommend Favorite

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer

By Losson Hélène   Schnekenburger Michael   Dicato Mario   Diederich Marc  

Molecules, Vol. 21, Iss. 11, 2016-11 ,pp. : 1608-1608

MDPI

Access to resources Recommend Favorite

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells

By Librizzi Mariangela   Spencer John   Luparello Claudio  

International Journal of Molecular Sciences, Vol. 17, Iss. 8, 2016-07 ,pp. : 1235-1235

MDPI

Access to resources Recommend Favorite

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

By Bishton Mark J.   Johnstone Ricky W.   Dickinson Michael   Harrison Simon   Prince H. Miles  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2674-2688

MDPI

Access to resources Recommend Favorite